FDMT Stock Analysis: Buy, Sell, or Hold?
FDMT - 4D Molecular Therapeutics, Inc. Common Stock
$11.60
1.18 (11.32%)
▲
5d:
+25.81%
30d:
+33.49%
90d:
+25.68%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When FDMT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: FDMT is 17.3% above its trading range ($9.89). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: FDMT is 17.3% above its trading range ($9.89). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: FDMT is currently trading at $11.60, which is considered extended relative to its 30-day fair value range of $8.46 to $9.89.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $11.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.3% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+143.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FDMT is showing sideways momentum. The price is approaching resistance at $11.73. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.3% recently.
Market Sentiment: FDMT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.22 (+143.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.46 -
$9.89
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+17.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.3%)
- BULLISH: Trading 143.3% below Wall St target ($28.22)
- WARNING: Recommendation downgraded due to 17.3% overvaluation
Trading Range Analysis
30-Day Trading Range
$8.46 -
$9.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$8.37
Resistance Level
$11.73
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.12
Wall Street Target
$28.22
(+143.3%)
Revenue Growth (YoY)
21664.3%
Profit Margin
-182.3%
Share & Embed Analysis
Last updated: June 23, 2026 7:30 PM ET
Data refreshes hourly during market hours. Next update: 8:30 PM
Data refreshes hourly during market hours. Next update: 8:30 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FDMT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Ashoo Gupta
SELL
390 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 64 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 65 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
